Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-12-05
2010-06-29
Babic, Christopher M. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07745133
ABSTRACT:
The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and/or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and/or breast cancer, due to germline mutation of a NBS1 gene.
REFERENCES:
patent: 6458534 (2002-10-01), Conconnon
patent: 7319007 (2008-01-01), Cybulski et al.
Lucentini et al. (The Scientist (2004) vol. 18).
Wacholder et al. (J. Natl. Cancer Institute (2004) 96(6):434-442).
Allen et al. (DDT:Targets (2004) 3(6): 183-190).
Zondervan et al. (Nature Reviews (2004) vol. 5: 89-99).
Stumm et al. (“No evidence for deletions of the NBS1 gene in lymphomas” Cancer Genet Cytogenet. Apr. 1, 2001;126(1):60-2).
Carlomango et al. (“Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer” Genes Chromosomes Cancer. Aug. 1999;25(4):393-5).
File History of U.S. Appl. No. 10/867,578, filed Jun. 14, 2004.
Carney, James P., et al., “The hMrell/HRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response”, Cell, 93(3), (May 1, 1998), 477-486.
Carpten, J. et al., “Germline mutations in the ribonuclease L gene in families showing linkage with HPC1”, Nature Genetics, 30(2), (Feb. 2002), 181-184.
Cybulski, C., et al., “CHEK2 Is a Multiorgan Cancer Susceptibility Gene”, Am. J. Hum. Genet. vol. 75, (2004), 1131-1135.
Cybulski, C., et al., “NBS1 is a prostate cancer susceptibility gene”, Cancer Research, 64(4), (Feb. 15, 2004), 1215-1219.
Debniak, Tadeusz, “Germline 657del5 mutation in the NBS1 gene in patients with malignant melonama of the skin”, Melanoma Research, 13, (2003), 365-370.
Digweed, J., “Human genetic instability syndromes: single gene defects with increased risk of cancer”, Toxical Lett. 67(1-3), (Apr. 1993), 259-81.
Dong, Xiangyang, et al., “Mutations in CHEK2 Associated with Prostate Cancer Risk”, Am. J. Hum. Genet. vol. 72, (2003), 270-280.
Fan, Zuohen, et al., “Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation”, Cancer Gene Therapy, vol. 7, (2000), 1307-1314.
Futaki, Makoto, “Chromosomal breakage syndromes and the BRCA1 genome surveillance complex”, Trends in Molecular Medicine, 7(12), (Dec. 2001), 560-565.
Gayther, Simon A., et al., “The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators”, Cancer Research, 60 (16), (Aug. 15, 2000), 4513-4518.
Gorski, Bohdan, et al., “Germline 657del5 Mutation in the NBS1 Gene in Breast Cancer Patients”, Int. J. Cancer, 106, (2003), 379-381.
Koivisto, Pasi A., et al., “Amplification of the Androgen Receptor Gene is Associated with P53 Mutation in Hormone-Refractory Recurrent Prostate Cancer”, Journal of Pathology, vol. 187, (1999), 237-241.
Lichtenstein, Paul, et al., “Environmental and Heritable Factors in the Causation of Cancer”, The New England Journal of Medicine, 343(2), (Jul. 13, 2000), 78-85.
Matsuura, Shinya, et al., “Positional cloning of the gene for Nijmegen breakage syndrome”, Nature Genetics, 19 (Jun. 1998), 179-181.
Plisiecka-Halasa, J., “Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours”, Ann. Hum. Genet., vol. 66, (2002), 353-359.
Rebbeck, Timothy R., et al., “Association of HPC2/ELAC2 Genotypes and Prostate Cancer”, Am. J. Hum. Genet. vol. 67, (2000), 1014-1019.
Seemanova, E., “An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability”, Mutation Research, 238, (1990), 321-324.
Steffen, J. et al., “Frequency of the heterozygous germline NBS1 mutation 657del5 in cancer patients from Poland”, Casopis Lekaru Ceskych, 141(8), International Workshop on Nijmegen Breakage Syndrome, Prague, Czech Republic, (2002), VII-VIII.
Steffen, Jan, et al., “Increased Cancer risk of Heterozygotes with NBS1 Germline Mutation in Poland”, Int. J. Cancer., vol. 111 (2004), 67-71.
Tavtigian, Sean V., et al., “A candidate prostate cancer susceptibility gene at chromosome 17p”, Nature Genetics, 27, (Feb. 2001), 172-180.
Van der Burgt, Ineke, et al., “Nijmegen breakage syndrome”, J. Med. Genet. 33(2), (Feb. 1996), 153-156.
Varon, Raymonda, “Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5 in three Slav populations”, European Journal of Human Genetics, vol. 8, (2000), 900-902.
Varon, Raymonda, “Mutations in the Nijmegen Breakage Syndrome Gene (NBS1) in Childhood Acute Lynphoblastic Leukemia (ALL)”, Cancer Research, vol. 61, (May 1, 2001), 3570-3572.
Varon, Ramonda, “Nibrin, a Novel DNA Double-strand Break Repair Protein, Is Mutated in Nijmegen Breakage Syndrom”, Cell, vol. 93, (May 1, 1998), 467-476.
Voelkel-Johnson, Christina, et al., “Genomic instability-based transgenic models of prostate cancer”, Carcinogenesis, 21(8), (2000), 1623-1627.
Wang, Liang, et al., “Role of HPC/ELAC2 in Hereditary Prostate Cancer1”, Cancer Research, vol. 61, (Sep. 1, 2001), 6494-6499.
Xu, J., et al., “Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or specific prostate cancer”, Am. J. Hum Genet., (68(4), (Apr. 2001), 901-11.
Xu, Jiangeng, et al., “Genomewide Screen and Identification of Gene-Gene Interactions for Asthma-Susceptibility Loci In Three U.S. Populations: Collaborative Study on the Genetics of Asthma”, American Journal of Human Genetics, 68, (Jun. 2001), 1437-1446.
Carlomango et al., “Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer”, Genes Chromosomes Cancer, (1999) 25(4):393-5.
Stumm et al., “No evidence for deletions of the NBS1 gene in lymphomas”, Cancer Genet Cytogenet (2001) 126(1):60-2.
Byrski Tomasz
Cybulski Cezary
Debniak Tadeusz
Gliniewicz Bartlomiej
Gorski Bohdan
Babic Christopher M.
Cooper & Dunham LLP
Gershik Gary J.
Pomeranian Academy of Medicine
LandOfFree
Determining a predisposition to cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determining a predisposition to cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining a predisposition to cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248999